Prakiraan wutah bathi resik saben saham kanggo taun ngarep Silexion (SLXN)

Logo korporat perusahaan Silexion Therapeutics (SLXN)

The closed loop of RNA engineering and clinic quotas in the US and Israel limit patient reach, which determines the cost dynamics for Silexion Therapeutics Corp (SLXN). The projected growth in the company's net profit demonstrates these complexities, where the value of 60.30 expresses the metric level. The absence of revenue due to the pre-commercial status of R&D and geopolitical barriers in biomaterial logistics make the generation of a stable cash flow virtually unattainable.

Silexion (SLXN): Prakiraan wutah bathi resik saben saham kanggo taun ngarep saka 17.08.2024 nganti 18.11.2026

Ringkesan rincian data analitis Silexion Therapeutics Corp (SLXN)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:Silexion Therapeutics Corp.
Produk dadi Silexion

For Silexion Therapeutics Corp (SLXN), which develops personalized RNA cancer therapies, the forward earnings per share (EPS) growth forecast reflects the consensus valuation of the future profitability of its innovative developments. This indicator measures the expected net income dynamics, filtering out market noise and allowing investors to assess the fundamental capitalization potential of Silexion Therapeutics Corp (SLXN) through the lens of the probable commercial success of its gene technologies.

Analisis pesaing Silexion Therapeutics Corp

INCY (incyte.com) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep hutch-med.com HCM|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Nuvation Corp (NUVB)|DAWN - Prakiraan wutah bathi resik saben saham ing taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Monopar Pharma MNPR|Inhibrx Corp - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|IMAB - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Fennec Pharmaceuticals|HRTX: Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep Nuvectis NVCT|Prakiraan wutah bathi saben saham kanggo taun ngarep CHRS|Prakiraan wutah bathi resik saben saham ing taun ngarep Corbus Pharmaceuticals CRBP|Prakiraan wutah bathi saben saham kanggo taun ngarep CRDF (Cardiff Oncology Inc.)|BYSI (BeyondSpring) - Dinamika bathi saben saham sing diarepake ing taun ngarep|BioAtla - Prakiraan wutah bathi saben saham kanggo taun ngarep|Proyeksi tambahing bathi saben saham ing taun ngarep LIXT (Lixte Biotechnology Holdings, Inc.)|Citius Pharmaceuticals, Inc. - Prakiraan wutah bathi kanggo taun ngarep|Dinamika bathi saben saham sing diarepake ing taun ngarep CLRB (Cellectar)|BLRX: Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep canfite.com (CANF)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep aprea.com|KZIA: Dinamika bathi saben saham sing diarepake ing taun ngarep|Prakiraan wutah bathi kanggo taun ngarep NCNA|Prakiraan wutah bathi kanggo taun ngarep Chimerix Inc (CMRX)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep|KRON: Prakiraan wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham ing taun ngarep Kintara Therapeutics Inc|oncternal.com (ONCT) - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep PRTG (Portage Biotech Corp)